These findings indicate that ERβ targeted therapies may still elicit anti-cancer effects in tumors with heterogenous expression of ERβ, a possibility that will need to be confirmed in cell line and PDX tumor models as well as clinical trials. Here, ESR2 is linked to neoplasm.